Reviewed by Michael Gill, B. Sc.
25 Lung Disease Clinical Trials Near Me
Top Hospitals for Lung Disease Clinical Trials
Image of Massachusetts General Hospital in Massachusetts.
Massachusetts General Hospital
Boston
6Active Trials
18All Time Trials for Lung Disease
1994First Lung Disease Trial
Image of Mayo Clinic in Minnesota.
Mayo Clinic
Rochester
5Active Trials
28All Time Trials for Lung Disease
2006First Lung Disease Trial
Most Recent Lung Disease Clinical Trials
Top Treatments for Lung Disease Clinical Trials
Treatment Name
Active Lung Disease Clinical Trials
All Time Trials for Lung Disease
First Recorded Lung Disease Trial
Ralinepag
3
3
2018
Nintedanib
2
12
2017
Abatacept
2
4
2017
furmonertinib 160 mg
1
1
2022
Furmonertinib
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Lung Disease
Treatment
Year
Sponsor
CSJ117
2021
Novartis Pharmaceuticals
Lemborexant 10 mg
2020
Eisai Inc.
Ensifentrine
2020
Verona Pharma plc
Nintedanib (Ofev®)
2019
Boehringer Ingelheim
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
2019
Mayo Clinic
Nintedanib
2019
Boehringer Ingelheim

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: October 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013 Oct 16;310(15):1591-600. Erratum in: JAMA. 2014 Feb 12;311(6):625. Padhke, Rahul [corrected to Phadke, Rahul]. https://pubmed.ncbi.nlm.nih.gov/241085012 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9. https://pubmed.ncbi.nlm.nih.gov/114018963 Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967 Feb 16;276(7):357-68. https://pubmed.ncbi.nlm.nih.gov/53346134 Vogiatzis I, Nanas S, Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur Respir J. 2002 Jul;20(1):12-9. https://pubmed.ncbi.nlm.nih.gov/121665585 Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusch K, Levvey BJ, Lund LH, Meiser B, Rossano JW, Stehlik J; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant. 2017 Oct;36(10):1047-1059. doi: 10.1016/j.healun.2017.07.016. Epub 2017 Jul 19. Review. https://pubmed.ncbi.nlm.nih.gov/287843246 Shukla Y, Wheatley A, Kirby M, Svenningsen S, Farag A, Santyr GE, Paterson NA, McCormack DG, Parraga G. Hyperpolarized 129Xe magnetic resonance imaging: tolerability in healthy volunteers and subjects with pulmonary disease. Acad Radiol. 2012 Aug;19(8):941-51. doi: 10.1016/j.acra.2012.03.018. Epub 2012 May 15. https://pubmed.ncbi.nlm.nih.gov/225917247 Montesi SB, Izquierdo-Garcia D, Désogère P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. https://pubmed.ncbi.nlm.nih.gov/311617708 Désogère P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384). pii: eaaf4696. doi: 10.1126/scitranslmed.aaf4696. https://pubmed.ncbi.nlm.nih.gov/283815379 Kirby M, Heydarian M, Svenningsen S, Wheatley A, McCormack DG, Etemad-Rezai R, Parraga G. Hyperpolarized 3He magnetic resonance functional imaging semiautomated segmentation. Acad Radiol. 2012 Feb;19(2):141-52. doi: 10.1016/j.acra.2011.10.007. Epub 2011 Nov 21. https://pubmed.ncbi.nlm.nih.gov/2210428810 Svenningsen S, Kirby M, Starr D, Leary D, Wheatley A, Maksym GN, McCormack DG, Parraga G. Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation. J Magn Reson Imaging. 2013 Dec;38(6):1521-30. doi: 10.1002/jmri.24111. Epub 2013 Apr 15. https://pubmed.ncbi.nlm.nih.gov/23589465